Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Monday, up 2.47% from the previous trading day, before settling in for the closing price of $26.68. Over the past 52 weeks, APLS has traded in a range of $26.28-$73.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 73.14%. While this was happening, its average annual earnings per share was recorded 70.32%. With a float of $100.98 million, this company’s outstanding shares have now reached $119.56 million.
Let’s determine the extent of company efficiency that accounts for 706 employees. In terms of profitability, gross margin is 85.99%, operating margin of -52.52%, and the pretax margin is -53.59%.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.07%, while institutional ownership is 94.04%. The most recent insider transaction that took place on Sep 16 ’24, was worth 1,340,597. In this transaction Director of this company sold 37,000 shares at a rate of $36.23, taking the stock ownership to the 100,000 shares. Before that another transaction happened on Sep 16 ’24, when Company’s VP/Chief Accounting Officer sold 192 for $36.21, making the entire transaction worth $6,952. This insider now owns 38,141 shares in total.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.17 earnings per share (EPS), lower than consensus estimate (set at -0.85) by -0.32. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.30% during the next five years compared to -13.70% drop over the previous five years of trading.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 4.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.74, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Looking closely at Apellis Pharmaceuticals Inc (NASDAQ: APLS), its last 5-days average volume was 2.59 million, which is a jump from its year-to-date volume of 1.69 million. As of the previous 9 days, the stock’s Stochastic %D was 33.72%. Additionally, its Average True Range was 1.32.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 6.06%, which indicates a significant decrease from 45.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.65% in the past 14 days, which was lower than the 51.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.98, while its 200-day Moving Average is $45.72. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $27.87. Second resistance stands at $28.40. The third major resistance level sits at $29.00. If the price goes on to break the first support level at $26.74, it is likely to go to the next support level at $26.14. Now, if the price goes above the second support level, the third support stands at $25.61.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 3.33 billion has total of 121,366K Shares Outstanding. Its annual sales at the moment are 396,590 K in contrast with the sum of -528,630 K annual income. Company’s last quarter sales were recorded 199,690 K and last quarter income was -37,660 K.
